Rigel Pharmaceuticals (RIGL) Cash from Financing Activities (2010 - 2026)

Rigel Pharmaceuticals' Cash from Financing Activities history runs 17 years deep, the most recent figure standing at -$10.9 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities fell 2355.99% year-over-year to -$10.9 million; the TTM figure through Mar 2026 stood at -$10.8 million (down 24.95% YoY), while the FY2025 annual figure was $601000.0, up 105.16% from the prior year.
• Cash from Financing Activities was -$10.9 million for Q1 2026 at Rigel Pharmaceuticals, down from -$4.6 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $19.1 million in Q1 2023 to a low of -$10.9 million in Q1 2026.
• Historically, Cash from Financing Activities has averaged $174000.0 across 5 years, with a median of -$373000.0 in 2023.
• The sharpest annual moves came in 2022 and 2026: Cash from Financing Activities surged 1911.31% in 2022, then slumped 2355.99% in 2026.
• A 5-year view of Cash from Financing Activities shows it stood at -$2.1 million in 2022, then soared by 123.19% to $486000.0 in 2023, then surged by 201.44% to $1.5 million in 2024, then sank by 412.08% to -$4.6 million in 2025, then slumped by 138.82% to -$10.9 million in 2026.
• The last three Cash from Financing Activities figures came in at -$10.9 million (Q1 2026), -$4.6 million (Q4 2025), and $4.3 million (Q3 2025), per Business Quant data.